Who is eligible for clinical trial NCT07285213?

Participants must meet protocol criteria for Clostridioides Difficile Infection. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07285213 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-11

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody (NCT07285213)

A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AZD5148 for Prevention of Recurrence of Clostridioides Difficile Infection in Individuals 18 Years of Age and Above

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18 years of age and above.

Who can join: Review the eligibility criteria below.

Location: Research Site — Phoenix, Arizona

Age range: 18 Years

🧪 Interventions in This Study

AZD5148 (DRUG)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (116 Sites)

Showing the first 25 of 116 sites.

Research Site — Phoenix, Arizona
Research Site — Chula Vista, California
Research Site — Sacramento, California
Research Site — Torrance, California
Research Site — Hamden, Connecticut
Research Site — Gainesville, Florida
Research Site — Hialeah, Florida
Research Site — Homestead, Florida
Research Site — Jacksonville, Florida
Research Site — Miami Lakes, Florida
Research Site — Miramar, Florida
Research Site — Port Orange, Florida
Research Site — Tamarac, Florida
Research Site — Tampa, Florida
Research Site — Athens, Georgia
Research Site — Atlanta, Georgia
Research Site — Idaho Falls, Idaho
Research Site — Burr Ridge, Illinois
Research Site — Lexington, Kentucky
Research Site — Louisville, Kentucky
Research Site — New Orleans, Louisiana
Research Site — Glen Burnie, Maryland
Research Site — Potomac, Maryland
Research Site — Boston, Massachusetts
Research Site — Boston, Massachusetts

📞 Contact the Study Coordinator

Phone: (877) 240-9479

Email: information.center@astrazeneca.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Clostridioides Difficile Infection

LMN-201 for Prevention of C. Difficile Infection Recurrence — Escondido, California
Evaluation of GeoHAI Implementation — Columbus, Ohio
Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy — Milwaukee, Wisconsin
Lifestyle and Recurrent Clostridioides Difficile Infection (CDI) — Ann Arbor, Michigan
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) — Charlottesville, Virginia
Secondary Prevention of Clostridioides Difficile Using Vancomycin — Montreal, Quebec

Explore by condition: All Clostridioides Difficile Infection clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗